{"id":"W3034504576","doi":"10.1093/crocol/otaa049","title":"Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis","year":2020,"lang":"en","type":"article","venue":"Crohn s & Colitis 360","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Kyowa Kirin Pharmaceutical Development","keywords":"Medicine; Placebo; Ulcerative colitis; Gastroenterology; Clinical endpoint; Internal medicine; Adverse effect; Pharmacodynamics; Ascending colon; Phases of clinical research; Monoclonal antibody; Population; Randomized controlled trial; Pharmacokinetics; Clinical trial; Surgery; Antibody; Immunology; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003684559,0.0003739262,0.0007813694,0.0001074901,0.0001463126,0.00007853832,0.0003325008,0.0001859079,0.000110469],"category_scores_gemma":[0.0002691813,0.0004003637,0.0001965959,0.0002100233,0.000268783,0.00004344916,0.0001858237,0.0002216426,0.00001086607],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005066661,"about_ca_system_score_gemma":0.000343064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002190213,"about_ca_topic_score_gemma":0.000409218,"domain_scores_codex":[0.9968665,0.0008484142,0.0006966058,0.0007805242,0.0003022654,0.000505698],"domain_scores_gemma":[0.9986414,0.00005148516,0.0002729939,0.0004034906,0.0002718664,0.0003587327],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8851008,0.005578266,0.008188548,0.0002709232,0.00109301,0.004640646,0.0127349,0.001712014,0.07369649,0.002407396,0.0005343604,0.004042593],"study_design_scores_gemma":[0.3140513,0.001673779,0.630502,0.00007340385,0.0001935431,0.00002596998,0.00448062,0.005998762,0.041533,0.0001868256,0.0003510763,0.0009297183],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958379,0.00008692882,0.0002632937,0.00006652839,0.0001232595,0.002034327,0.0003936841,0.00002958078,0.001164453],"genre_scores_gemma":[0.9985465,0.00006312213,0.0001299266,0.0002810497,0.0002724601,0.0001991294,0.0003910184,0.00005445005,0.00006236627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6223134,"threshold_uncertainty_score":0.9998448,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02534543814436496,"score_gpt":0.3252506905611766,"score_spread":0.2999052524168116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}